Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up

PLoS One. 2013;8(3):e57904. doi: 10.1371/journal.pone.0057904. Epub 2013 Mar 1.

Abstract

Purpose: To study changes of iron content in basal ganglia in Parkinson's disease (PD) through a three-year longitudinal follow-up of the effective transverse relaxation rate R2*, a validated MRI marker of brain iron content which can be rapidly measured under clinical conditions.

Methods: Twenty-seven PD patients and 26 controls were investigated by a first MRI (t0). Longitudinal analysis was conducted among the 18 controls and 14 PD patients who underwent a second MRI (t1) 3 years after. The imaging protocol consisted in 6 gradient echo images obtained at different echo-times for mapping R2*. Quantitative exploration of basal ganglia was performed by measuring the variation of R2* [R2*(t1) - R2*(t0)] in several regions of interest.

Results: During the three-year evolution of PD, R2* increased in Substantia nigra (SN) (by 10.2% in pars compacta, p = 0.001, and 8.1% in pars reticulata, p = 0.013) and in the caudal putamen (11.4%, p = 0.011), without significant change in controls. Furthermore, we showed a positive correlation between the variation of R2* and the worsening of motor symptoms of PD (p = 0.028).

Conclusion: Significant variation of R2* was longitudinally observed in the SN and caudal putamen of patients with PD evolving over a three-year period, emphasizing its interest as a biomarker of disease progression. Our results suggest that R2* MRI follow-up could be an interesting tool for individual assessment of neurodegeneration due to PD, and also be useful for testing the efficiency of disease-modifying treatments.

MeSH terms

  • Aged
  • Basal Ganglia / metabolism
  • Basal Ganglia / pathology*
  • Biomarkers / metabolism
  • Case-Control Studies
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Iron / metabolism*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Parkinson Disease / diagnosis
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology*
  • Putamen / metabolism
  • Putamen / pathology*
  • Reticular Formation / metabolism
  • Reticular Formation / pathology*
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology*

Substances

  • Biomarkers
  • Iron

Grants and funding

The authors have no funding or support to report.